BioSpace News Archive

Drug Development

Chipscreen NewWay: First Patient Dosed in Phase 1 Trial of the Bispecific Antibody NWY001, a Next-generation Tumor Immunotherapy in Patients with Advanced Solid Tumors

Chengdu Chipscreen NewWay Biosciences Co., Ltd. announced that on January 5, 2024, the dosing of the first patient for a phase I clinical trial of a PD-1/CD40 bispecific antibody, NWY001, at Sun Yat-Sen University Cancer Center in China, the trial-leading institution.

January 16, 2024
·
5 min read
Drug Development

AM-Pharma Initiates Phase 2 Trial of Ilofotase Alfa for Cardiac Surgery-Associated Renal Damage

AM-Pharma B.V. announced that the first patients have been treated in a Phase 2 clinical study evaluating the company’s proprietary recombinant alkaline phosphatase, ilofotase alfa, as a preventive treatment for cardiac surgery-associated renal damage.

January 16, 2024
·
5 min read
Biotech Beach

Reflow Medical Receives CE Mark for Bare Temporary Spur Stent System for Treating de novo or Restenotic Below-the-Knee (BTK) Lesions

Reflow Medical, Inc., a developer of innovative medical devices focused on cardiovascular disease, announces it has received CE Mark certification in the European Union for the Bare Temporary Spur Stent System.

January 16, 2024
·
3 min read
Biotech Bay

Augmedix Announces Participation in Maxim Group Virtual Healthcare IT Investor Conference

Augmedix, Inc. announced that it will participate in the Maxim Group Virtual Healthcare IT Conference on January 24, 2024.

January 16, 2024
·
1 min read
BioMidwest

ASCEND’s Telepresence Technology, Catalyst LIVE, Transforms Diagnostic Imaging

ASCEND Cardiovascular’s newest technology, Catalyst LIVE, currently implemented at two pioneering hospital sites, has pilots underway since 2022 at Stanford Medicine Children’s Health in California and Cook County Health in Illinois.

January 16, 2024
·
3 min read
Policy

Eyenovia Re-Acquires Development and Commercialization Rights to MicroPine in the U.S. and Canada

Eyenovia, Inc., a commercial-stage, ophthalmic company, announced that it has re-acquired the rights to MicroPine in the U.S. and Canada.

January 16, 2024
·
6 min read
Business

Julie Andrews Begins as New Chief Financial Officer at Orthofix

Orthofix Medical Inc . (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced that Julie Andrews has officially stepped into the role of Chief Financial Officer (CFO).

January 16, 2024
·
5 min read
BioForest

LumiThera Announces Initiation of EUROLIGHT Registry Study to Evaluate Long-term Benefits of Photobiomodulation (PBM) Treatment using the Valeda® Light Delivery System

LumiThera Announces Initiation of EUROLIGHT Registry Study to Evaluate Long-term Benefits of Photobiomodulation (PBM) Treatment using the Valeda ® Light Delivery System in Patients with Dry Age-Related Macular Degeneration (AMD).

January 16, 2024
·
5 min read
Emergex Announces R&D Collaboration with DEKA Research & Development Corp. for Assessment of Emergex’s Immunotherapeutic Candidates with DEKA’s Intradermal Therapeutic Applicator

Emergex Vaccines Holding Limited announced that the Company has entered into an agreement with DEKA to assess the compatibility of Emergex’s immunotherapeutic candidates with the DEKA Intradermal Therapeutic Applicator.

January 16, 2024
·
5 min read
Drug Development

Anavex Life Sciences Announces U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia

Anavex Life Sciences Corp. today announced the initiation of the U.S. FDA cleared placebo-controlled Phase 2 trial of ANAVEX®3-71 for the treatment of schizophrenia, which is expected to begin in Q2 2024. ANAVEX®3-71 positive initial Phase 1 results in healthy volunteers were previously reported.

January 16, 2024
·
8 min read